Tag Archive for: lenacapavir

The U.S. Food and Drug Administration (FDA) on Thursday approved Gilead Sciences Inc.’s Sunlenca therapy for HIV infections, paving the way for a drug that requires less frequent dosing than existing treatments.

Gilead Sciences Inc. on Thursday posted a higher-than-expected third-quarter profit on the back of strong demand for its HIV and cancer drugs, which helped offset lower sales of its COVID-19 antiviral drug and acquisition expenses.

Gilead’s regulatory win could open the doors for patients with complicated medication histories and for whom viral suppression regimens have become difficult to create.

Gilead’s total revenue for Q2 increased 1% to $6.3 billion compared to Q2 in 2021. Overall, the company exceeded both its own expectations and the predictions of market analysts for the second quarter.